Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Zeitlin

Showing results (31-40 of 161) with videos related to

Pageof 17
Sort By:
American Journal of Respiratory and Critical Care Medicine|February 26, 1998
A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR functionR C Rubenstein, P L Zeitlin
Archives of Internal Medicine|June 1, 1978
Neuromuscular disease in tertiary hyperparathyroidismR E Gerhardt, E L Zeitlin
Clinical Reviews in Allergy & Immunology|May 22, 2008
Atypical cystic fibrosis and CFTR-related diseasesShruti M Paranjape, Pamela L Zeitlin
American Journal of Physiology. Lung Cellular and Molecular Physiology|June 19, 2001
Induction of HSP70 promotes DeltaF508 CFTR traffickingL R Choo-Kang, P L Zeitlin
Journal of Medical Case Reports|May 27, 2008
Cystic fibrosis presenting as recurrent pancreatitis in a young child with a normal sweat test and pancreas divisum: a case reportLaurie Conklin, Pamela L Zeitlin, Carmen Cuffari
The Journal of Biological Chemistry|April 20, 2006
Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implicationsNeeraj Vij, Shengyun Fang, Pamela L Zeitlin
Current Opinion in Pulmonary Medicine|December 2, 2000
Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapyL R Choo-Kang, P L Zeitlin
Plos One|February 28, 2009
CFTR is a negative regulator of NFkappaB mediated innate immune responseNeeraj Vij, Steven Mazur, Pamela L Zeitlin
Emerging Infectious Diseases|March 19, 1999
Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseasesL Zeitlin, R A Cone, K J Whaley
Journal of Cellular Biochemistry|September 25, 2003
Effects of long-term administration of N-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) miceL Zeitlin, E Segev, A Fried, et al.
Pageof 17

Showing results (31-40 of 161) with videos related to

Sort By:
Pageof 17
American Journal of Respiratory and Critical Care Medicine|February 26, 1998
A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR functionR C Rubenstein, P L Zeitlin
Archives of Internal Medicine|June 1, 1978
Neuromuscular disease in tertiary hyperparathyroidismR E Gerhardt, E L Zeitlin
Clinical Reviews in Allergy & Immunology|May 22, 2008
Atypical cystic fibrosis and CFTR-related diseasesShruti M Paranjape, Pamela L Zeitlin
American Journal of Physiology. Lung Cellular and Molecular Physiology|June 19, 2001
Induction of HSP70 promotes DeltaF508 CFTR traffickingL R Choo-Kang, P L Zeitlin
Journal of Medical Case Reports|May 27, 2008
Cystic fibrosis presenting as recurrent pancreatitis in a young child with a normal sweat test and pancreas divisum: a case reportLaurie Conklin, Pamela L Zeitlin, Carmen Cuffari
The Journal of Biological Chemistry|April 20, 2006
Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implicationsNeeraj Vij, Shengyun Fang, Pamela L Zeitlin
Current Opinion in Pulmonary Medicine|December 2, 2000
Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapyL R Choo-Kang, P L Zeitlin
Plos One|February 28, 2009
CFTR is a negative regulator of NFkappaB mediated innate immune responseNeeraj Vij, Steven Mazur, Pamela L Zeitlin
Emerging Infectious Diseases|March 19, 1999
Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseasesL Zeitlin, R A Cone, K J Whaley
Journal of Cellular Biochemistry|September 25, 2003
Effects of long-term administration of N-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) miceL Zeitlin, E Segev, A Fried, et al.
Pageof 17